AstraZeneca PLC ADR Stock Forecast:
Based on the forecast of 7 analysts, the average target price for AstraZeneca PLC ADR stock over the next 12 months is USD 87.60. The average analyst rating for the stock is Strong Buy. However, Stock Target Advisor‘s own analysis rates the stock as Neutral, based on 8 positive signals and 7 negative signals. As of the last closing, the stock price of AstraZeneca PLC ADR was USD 72.59. Over the past week, the stock price has increased by +0.10%, but over the past month, it has decreased by -2.41%. However, looking at the performance over the last year, the stock has shown a positive change of +10.49%.
AstraZeneca Plc. News:
AstraZeneca Plc, has achieved a major breakthrough in the treatment of lung cancer with its flagship drug, Tagrisso. Clinical trial data presented at the American Society of Clinical Oncology (ASCO) meeting revealed that Tagrisso significantly reduces the risk of death by over 50% in patients with a specific type of lung cancer that can be surgically removed when diagnosed at an early stage. This latest development solidifies Tagrisso’s position as the primary treatment option for patients with EGFR-mutated lung cancer, placing it at the forefront of AstraZeneca’s portfolio.
Tagrisso, which generated an impressive $5.4 billion in revenue last year, is already recognized as a leading therapy for non-small cell lung cancer (NSCLC) patients who possess a mutation in the EGFR gene. The drug has received regulatory approvals in various regions, affirming its efficacy and safety profile for this specific patient population. However, the recently presented trial data further emphasizes the drug’s significance and establishes it as the backbone treatment for EGFR-mutated lung cancer.
Susan Galbraith, Executive Vice President of Oncology Research and Development at AstraZeneca, expressed her enthusiasm about the trial results, stating, “The latest data cements Tagrisso’s position as the cornerstone treatment for EGFR-mutated lung cancer.” Galbraith’s statement reflects the immense impact of this breakthrough on patients’ lives and the future of lung cancer treatment.
The clinical trial that yielded the recent data enrolled patients with early-stage EGFR-mutated lung cancer who were eligible for surgical removal of their tumor. The trial demonstrated that Tagrisso treatment significantly reduced the risk of death compared to placebo, highlighting its potential to enhance patient outcomes and prolong survival. The findings have far-reaching implications, as they provide oncologists with compelling evidence to support the use of Tagrisso as an essential component of early-stage lung cancer treatment.
